Biodesix to buy U.S. lab, lung nodule test from Oncimmune
The deal, which would become effective Nov. 1, is valued at up to $28 million over the next five years. Biodesix will acquire the UK company's US lab in Kansas.
Biodesix acquires Seattle-based developer of blood-based lung nodule test
Acquisition of Integrated Diagnostics gives Biodesix control of test to determine if nodules are benign or malignant.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.